Head and Neck Cancer Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Head and Neck Cancer Therapeutics Market

Key players in the head and neck cancer therapeutics market have implemented significant tactics, including new product development, mergers and acquisitions, and strategic alliances with government authorities. Innovative medications and treatment approaches are being introduced by manufacturers to improve patients' quality of life. The provision of regulatory support has facilitated the development of a substantial medication pipeline by businesses, hence augmenting the likelihood of obtaining superior treatment compared to the existing methods in this domain. Here are some prominent players in the market:

Eli Lily and Company
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Sanofi S.A.
Merck & Co., Inc.
Clinigen Group plc
Bristol-Myers Squibb Company
Calliditas Therapeutics AB
Naveris, Inc.
AstraZeneca plc
Hoffman-La Roche Ltd.
Coherus BioSciences

Browse Key Market Insights with Data Illustration:

Head and Neck Cancer Therapeutics Market Size Forecasts 2037

In the News

In May 2024, Calliditas Therapeutics AB reported results from a proof-of-concept Phase 2 trial of setanaxib, its lead NOX enzyme inhibitor, in combination with pembrolizumab in patients with squamous cell carcinoma of the head and neck (SCCHN). The study found statistically significant increases in progression-free survival (PFS) and overall survival (OS), and statistically significant alterations in tumor biology that were consistent with setanaxib's mode of action.
In April 2024, Naveris, Inc., the market leader in precision oncology diagnostics for viral-induced cancers, announced the start of a Phase II clinical trial in HPV-driven head and neck cancer with minimum residual disease (MRD+). Memorial Sloan Kettering Cancer Center (MSKCC), a world-renowned cancer treatment and research institution, will lead the study.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of head and neck cancer therapeutics was over USD 1.9 billion.

The market size for head and neck cancer therapeutics is projected to cross USD 5.6 billion by the end of 2037 expanding at a CAGR of 9.1% during the forecast period i.e., between 2025-2037.

The major players in the market are Eli Lily and Company, Sanofi S.A., Merck & Co., Inc., Clinigen Group plc, Bristol-Myers Squibb Company, Calliditas Therapeutics AB, Naveris, Inc., AstraZeneca plc, Hoffman-La Roche Ltd., Coherus BioSciences, and others.

The injectable segment is anticipated to garner a share of 57.6% during 2025-2037.

The North America head and neck cancer therapeutics sector is poised to hold a 37.5% share by the end of 2037.

Head and Neck Cancer Therapeutics Market - Top Companies and Manufacturers

Companies Dominating the Head and Neck Cancer Therapeutics Market

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How big is the head and neck cancer therapeutics industry?

What is the outlook for the head and neck cancer therapeutics market?

Who are the major players dominating the head and neck cancer therapeutics landscape?

Which segment will capture the significant market share for head and neck cancer therapeutics by 2037?

Which region will provide more opportunities for the head and neck cancer therapeutics business by 2037?